Volume 25, Number 1—January 2019
Research
Risk Factors for Elizabethkingia Acquisition and Clinical Characteristics of Patients, South Korea
Table 4
Results of univariate and multivariate analysis using conditional logistic regression of risk factors for the acquisition of Elizabethkingia species at a tertiary teaching hospital after propensity score matching, Seoul, South Korea*
Variable | Univariate analysis | Multivariate analysis† | |||
---|---|---|---|---|---|
OR (95% CI) |
p value |
OR (95% CI) |
p value |
||
Ward | |||||
Ward A | Reference | ||||
Ward B | 0.87 (0.41–1.79) | 0.70 | |||
Intensive care unit 1 |
0.69 (0.18–2.22) |
0.56 |
|||
Period of admission | |||||
2016 Jan–Mar | Reference | ||||
2016 Apr–Jun | 8.03 (0.79–81.98) | 0.08 | |||
2016 Jul–Sep | 8.87 (0.74–105.84) | 0.08 | |||
2016 Oct–Dec | 10.62 (0.64–176.77) | 0.10 | |||
2017 Jan–Mar | 8.87 (0.97–81.16) | 0.05 | |||
2017 Apr–Jun |
8.34 (0.71–98.76) |
0.09 |
|||
Median stay in 3 wards, d | 1.01 (0.99–1.02) | 0.25 | |||
Age, y | 1.00 (0.98–1.02) | 0.87 | |||
Male sex | 1.06 (0.55–2.02) | 0.87 | |||
Charlson comorbidity index |
0.97 (0.85–1.12) |
0.69 |
|||
Comorbidities‡ | |||||
Solid organ tumor | 0.48 (0.21–1.08) | 0.08 | |||
Diabetes mellitus | 0.89 (0.34–2.31) | 0.81 | |||
Chronic pulmonary disease | 1.85 (0.55–6.28) | 0.32 | |||
Chronic kidney disease | 1.52 (0.60–3.85) | 0.38 | |||
Hematologic malignancy | 1.00 (0.25–4.00) | 0.99 | |||
Dementia | 0.57 (0.12–2.77) | 0.49 | |||
Connective tissue disease | 0.80 (0.21–3.05) | 0.75 | |||
Mild liver disease | 1.00 (0.10–9.61) | 0.99 | |||
Steroid use | 1.55 (0.62–3.89) | 0.35 | |||
Mechanical ventilation |
64.54 (8.76–475.30) |
<0.01 |
50.44 (6.74–377.48) |
<0.01 |
|
Antimicrobial exposure | |||||
Penicillin§ | 0.32 (0.07–1.54) | 0.16 | |||
1st-generation cephalosporin | 0.29 (0.03–2.88) | 0.29 | |||
2nd-generation cephalosporin | 3.00 (0.42–21.30) | 0.27 | |||
3rd-generation cephalosporin | 0.97 (0.46–2.01) | 0.93 | |||
4th-generation cephalosporin | NA | ||||
Aminoglycoside | 3.18 (1.21–8.31) | 0.02 | 2.30 (0.62–8.47) | 0.21 | |
Glycopeptide | 3.96 (1.82–8.63) | <0.01 | 1.72 (0.50–5.86) | 0.39 | |
Linezolid | 8.84 (0.97–80.69) | 0.05 | |||
Carbapenem | 4.16 (1.99–8.72) | <0.01 | 1.63 (0.55–4.85) | 0.38 | |
Tetracycline | 1.65 (0.42–6.43) | 0.47 | |||
Trimethoprim/sulfamethoxazole | 2.11 (0.90–4.91) | 0.09 | |||
Lincosamide | 6.00 (0.54–66.17) | 0.14 | |||
Macrolide | 0.75 (0.08–6.71) | 0.80 | |||
Fluoroquinolone | 3.42 (1.70–6.87) | <0.01 | 2.01 (0.71–5.69) | 0.19 | |
Other | 2.09 (0.48–9.03) | 0.33 |
*OR, odds ratio; NA, not available.
†Only variables with p<0.05 in the univariate model were included in the multivariate model.
‡May be multiple.
§Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
1These authors contributed equally to this article.